Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy

(1) Background: Neoadjuvant therapy is the main therapeutic strategy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, and the combination of trastuzumab and pertuzumab (HP) has become a routine treatment. How to predict and screen patients who are less likely to r...

Full description

Bibliographic Details
Main Authors: Jiayi Li, Shuang Zhang, Chen Ye, Qian Liu, Yuanjia Cheng, Jingming Ye, Yinhua Liu, Xuening Duan, Ling Xin, Hong Zhang, Ling Xu
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Journal of Personalized Medicine
Subjects:
breast cancer
androgen receptor
trastuzumab
pertuzumab
neoadjuvant therapy
pathologic complete response
Online Access:https://www.mdpi.com/2075-4426/12/2/261

Internet

https://www.mdpi.com/2075-4426/12/2/261

Similar Items